Clinical Trial Update: Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency [Phase 3]

View source ↗

Summary

Phase 3 trial of GC5101F intravenous immune globulin for primary humoral immunodeficiency was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency Disease

Drugs mentioned

• GC5101F (gc5101f)

Snippet

Sponsor: Green Cross Corporation | Conditions: Primary Immune Deficiency Disorder | Phase 3 | Status: WITHDRAWN